...internally developed product to gain the designation in China. Merck buys rest of Lumos voucher Lumos Pharma Inc....

...Lumos finds public pat h Rare disease company Lumos Pharma Inc. plans to go public via a reverse...
...with NewLink Genetics Corp. (NASDAQ:NLNK). Set to own about 50% of the combined company are Lumos’...
...which will retain Lumos’ name, plans to start a Phase IIb trial in mid-2020 of Lumos'...

...portfolio also includes cancer companies Iterion Therapeutics and Molecular Therapeutics Inc. and rare disease play Lumos Pharma Inc....

...Mauro as CMO. He was EVP and CMO at Advaxis Inc. (NASDAQ:ADXS). Rare disease company Lumos Pharma Inc....

...He was SVP and head of worldwide medical at Biogen Inc. (NASDAQ:BIIB). Orphan disease company Lumos Pharma Inc....

...also participated, as did existing investors New Enterprise Associates, Sante Ventures and UCB Group (Euronext:UCB). Lumos'...
...but cannot actively transport it across the blood-brain barrier. President and CEO Rick Hawkins said Lumos...
...trial in healthy volunteers and evaluate LUM-001 in a cohort of about 10 CTD patients. Lumos...

...Dompe began the 24-week, double-blind, vehicle-controlled, Italian Phase Ib/II Lumos trial to evaluate 60 and 180...